Hello Baby Reproductive Files for IPO: Building China's 'New Oxygen' in the Overseas Assisted Reproduction Market

“Some people hold the biased view that entrepreneurship is a last resort for those who cannot find employment or lack sufficient capabilities. In reality, however, entrepreneurs in the 21st century generally possess strong academic credentials and knowledge. The essence of our entrepreneurial journey is not to become mere businessmen, but to serve as entrepreneurs who contribute positively to society and benefit the public.” This reflects the sincere original aspiration of Zhang Tonghua, founder of “Hello Baby Reproductive Health,” when discussing his venture into entrepreneurship.

Zhang Tonghua joined Chunyu Yisheng (Spring Rain Doctor) in her early career, following her fellow disciple and senior colleague Zhang Rui. This experience gave her a genuine appreciation for the challenges faced by startups in their nascent stages, and it was this unique journey that firmly set her on the path of the healthcare industry. “The focus of healthcare must not be on profitability, but on genuinely empowering industrial development with tangible value.” This is the ethical benchmark Zhang Tonghua has consistently upheld, as she emphasized in an interview.

“Hello Baby Reproduction” Founder, Zhang Tonghua

“Hello Baby Reproductive Health (Beijing Shiliujia Technology Co., Ltd.)” is a one-stop overseas assisted reproductive technology (ART) service platform independently established by Zhang Tonghua. It aims to provide overseas ART services to clients and families in China who are unable to conceive due to various reasons, including infertility caused by medical conditions, advanced maternal age, unexplained infertility, repeated failures of domestic assisted conception attempts, and genetic disorders.

The platform’s team members are primarily from Chunyu Doctor, Penguin Doctor, and large medical institutions, possessing professional expertise in both healthcare and internet thinking, as well as strong execution capabilities. Zhang Tonghua introduced that the “Hello Baby Reproductive” team launched version 1.0 of the platform within 50 days, completed a strategic transformation in 75 days, and validated a business model with over 600 egg-freezing reservations.

Zhang Tonghua’s decision to focus deeply on the assisted reproductive technology (ART) industry stems from his recognition of several key growth potentials in this sector.

From a capital perspective, assisted reproductive technology (ART) is a highly promising industry. As the first ART-focused company listed on the Hong Kong Stock Exchange, Jinxin Fertility conducts an average of 20,000–30,000 treatment cycles annually, with a valuation of approximately RMB 50 billion, characterized by its asset-heavy medical model. In 2021, Berry Genomics completed its IPO; the company specializes in genetic testing within the ART sector, generating an average annual revenue of around RMB 100 million and holding a valuation of approximately RMB 7–8 billion.

“Hello Baby Reproduction” Corporate Positioning

Amidst the intense competition from industry giants in the assisted reproductive technology (ART) sector, “Hello Baby Reproductive” focuses on a unique niche: the traffic gateway for ART services. Analogous to Beike in real estate and SoYoung in medical aesthetics, this segment has yet to be dominated by any major player in an era where traffic is king. This represents “Hello Baby Reproductive’s” strategic market positioning and the team’s unwavering commitment to securing the top spot as the leading traffic gateway in the ART field.

In contrast, the entire assisted reproductive technology (ART) industry currently relies primarily on intermediary services for resource matching. The prevailing operational model in the downstream ART sector involves recommending suitable ART hospitals to domestic clients through private personal networks. However, such independent intermediary services are difficult to standardize and pose numerous potential risks:

First, intermediaries primarily acquire customers through industry-specific channels, such as physician referrals and pharmaceutical sales representative networks. Due to the high customer acquisition costs associated with these relationship chains, prices offered to consumers remain difficult to reduce, ultimately leading to a "bad money drives out good" scenario.

IIFor Chinese users, due to information asymmetry regarding overseas medical services, they often lack a clear understanding of hospitals’ actual capabilities and are unsure which facilities are best suited for their specific conditions. As a result, they may blindly follow intermediaries’ arrangements, leaving them with no recourse for complaints even if assisted reproductive technology (ART) procedures, such as third-generation in vitro fertilization (IVF), fail.

III., as overseas assisted reproductive technology (ART) clinics lack strong brand recognition in China, their patient acquisition primarily relies on maintaining good relationships with intermediaries, which hinders these institutions from building brand awareness and sustaining patient inflow in the domestic market;

Finally, assisted reproductive technology (ART) is a highly specialized field in every country. The entire industry for local reception services remains niche compared to other service sectors such as general travel. This has led to unstable revenue and patient volumes for overseas ART service providers, while service quality and professionalism vary significantly, making standardization difficult.

In contrast, the advantages of “Internet+” have provided solutions to these pain points. Zhang Tonghua introduced that “Hello Baby Reproductive Health” is committed to making information more open and transparent, with all service providers and user reviews being verifiable, and only hospitals meeting specific standards are allowed to list on the platform. Moreover, “Hello Baby Reproductive Health” does not charge any intermediary fees to users seeking assisted reproductive services on the platform, thereby eliminating middlemen and reducing costs caused by information asymmetry. Finally, “Hello Baby Reproductive Health” optimizes the entire industry through supply chain integration, promoting survival of the fittest.

Currently, the one-stop overseas assisted reproductive services offered by "Hello Baby Reproductive" includeProfessional Medical ServicesandCustomizable End-to-End Support Services。

“One-Stop Overseas Assisted Reproductive Framework of ‘Hello Baby Fertility’”

Medical services primarily involve recommending and scheduling appointments with 11 leading hospitals across Thailand and Malaysia, tailored to users’ specific circumstances and needs, while providing comprehensive, end-to-end professional medical service management. The platform features a dedicated Medical Affairs Department staffed with reproductive health specialists, as well as a trained team of medical translators and customer service representatives, ensuring the professionalism of its services.

Customizable end-to-end support services are primarily designed to cover patients’ daily needs—such as clothing, food, accommodation, and transportation—during their overseas medical treatment. These comprehensive ancillary services include ticketing, airport pick-up and drop-off, lodging, local transportation, and dining. Clients can choose either bundled packages or à la carte options, ensuring flexible, convenient, and cost-effective solutions that meet diverse personalized requirements.

“Hello Baby Reproductive Health” not only excels in supply chain integration and management but has also established a professional, comprehensive, and standardized service management system. By integrating and managing the supply chain, it carefully selects and optimizes specialized medical institutions and high-quality local service provider teams. Through multi-dimensional management covering medical expertise, preferential healthcare policies, local service pricing, and customer experience, it recommends the highest-quality, personalized service teams to users.

Meanwhile, “Hello Baby Reproductive” has established a high-quality service management system through a model combining an in-house service team with third-party providers. Aligning with the 28-day IVF cycle, “Hello Baby Reproductive” not only matches oocyte cryopreservation users or individuals facing infertility with appropriate hospitals but also assigns dedicated medical consultants to each user. Prior to undergoing IVF or oocyte cryopreservation, users receive customized preconception care and consultation services tailored by a panel of domestic and international experts. Throughout the medical service process, professional medical translators/physician assistants provide auxiliary support, including interpretation of medical reports and treatment plans, medication guidance, and coordination of medical procedures. Additionally, professional customer service personnel offer end-to-end support. All these efforts are aimed at improving users’ reproductive success rates and enhancing their overall service experience.

On the other hand, another partner at “Hello Baby Reproductive” has been deeply engaged in the field of assisted reproduction for over a decade. The synergy between the two partners effectively enhances the overall value of the platform. By leveraging the internet and integrating the entire assisted reproduction service workflow, the platform migrates offline services online to streamline operations, improve efficiency, and establish an ecological closed-loop one-stop assisted reproduction platform.

In addition to providing third-generation IVF services, egg freezing is another major business line of “Hello Baby Fertility.” The service primarily targets unmarried and divorced single women. While China imposes specific medical indications for egg freezing, “Hello Baby Fertility” helps clients meet their egg-freezing needs by offering tailored solutions.

“Hellobaby Reproductive” provides professional, convenient, and affordable high-quality assisted reproductive services to the new middle class. By entering the underserved market of egg freezing, the platform shifts IVF demand upstream, catering to a larger base of potential users seeking fertility preservation, reproductive autonomy, and eugenic optimization. Through its platform model, it brings price transparency to reproductive institutions, visualizes reviews, standardizes service processes, and customizes ancillary services, thereby meeting diverse needs and leveraging egg freezing products to gain a first-mover advantage in the industry.

Furthermore, leveraging a well-known brand with ten years of experience in the field, “Hellobaby Reproductive Health” rapidly assessed and introduced 11 high-quality assisted reproductive technology (ART) institutions from Thailand and Malaysia during the pandemic. It also established a distinctive, comprehensive, end-to-end “online + offline” management system, integrating online promotion with conversion through offline city partners. The company quickly finalized its business model prototype, replicated its oocyte cryopreservation service line, and achieved a monthly compound growth rate of 125%, becoming the leading oocyte cryopreservation platform in China.

Notably, the compound annual growth rate of the egg freezing business maintained a positive trajectory even during the COVID-19 pandemic. Infertility patients with overseas IVF needs typically feel an urgent desire to have children; therefore, while their services were temporarily suspended amid the global pandemic, “Hellobaby Reproductive” primarily focused on providing IVF services to same-sex couples and families with a history of genetic diseases.

It is reported that “Hellobaby Reproductive Health” has established a strategic partnership with JD Health, while collaborations with Ping An Good Doctor, Tencent Health, and Alibaba Health are being progressively integrated. Currently, “Hellobaby Reproductive Health” has launched its fundraising initiative, prioritizing the inclusion of high-caliber institutions and individuals with resource-based or strategic advantages.